Search

Ocular Therapeutix Inc

Закрыт

СекторЗдравоохранение

10.64

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

10.59

Макс.

10.74

Ключевые показатели

By Trading Economics

Доход

9.8M

-79M

Продажи

2.7M

13M

Прибыль на акцию

-0.35

Рентабельность продаж

-584.512

Сотрудники

325

EBITDA

10M

-74M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+142.29% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

383M

2.3B

Предыдущая цена открытия

10.64

Предыдущая цена закрытия

10.64

Новостные настроения

By Acuity

29%

71%

62 / 339 Рейтинг в Healthcare

Ocular Therapeutix Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 сент. 2026 г., 20:01 UTC

Ocular Therapeutix Inc's shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain the decline.

2 сент. 2026 г., 23:31 UTC

Ocular Therapeutix shares were roughly flat in after-market hours. The broader market reacted to a weaker-than-expected ADP payrolls report.

1 сент. 2026 г., 19:46 UTC

Ocular Therapeutix Inc's shares are higher today, rebounding from earlier volatility and remaining well above the 20-day moving average.

31 авг. 2026 г., 21:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, showing strength despite broader market pressure from hawkish Fed remarks. No specific news was identified.

28 авг. 2026 г., 20:08 UTC

Ocular Therapeutix Inc shares are lower today, reflecting broader market declines amid rising U.S. Treasury yields and inflation concerns. No specific company news was identified.

27 авг. 2026 г., 21:01 UTC

Ocular Therapeutix Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26 авг. 2026 г., 19:36 UTC

Ocular Therapeutix Inc shares are lower today, with no specific news identified. This follows U.S. PCE data indicating inflationary pressures.

24 авг. 2026 г., 20:06 UTC

Social Media

Ocular Therapeutix Inc. shares are lower amid a lawsuit from EyePoint, Inc. and broader market pressures, despite a brief rebound earlier in the session.

22 авг. 2026 г., 00:02 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, maintaining momentum from Friday's close amid a broadly positive market performance.

21 авг. 2026 г., 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market trading, reflecting strong performance amid positive sentiment in related sectors and developments in the cryptocurrency market.

20 авг. 2026 г., 20:02 UTC

Ocular Therapeutix Inc is lower today amid broader market declines following Walmart's disappointing sales growth and guidance, contributing to increased selling pressure.

19 авг. 2026 г., 23:21 UTC

Ocular Therapeutix Inc shows modest gains in after-market trading, with no specific news identified for the price movement. The stock remains above its 20-day moving average.

18 авг. 2026 г., 22:26 UTC

Social Media

Ocular Therapeutix shares rise in after-market hours after Cowen set a $20 price target, and Baird raised its target to $30 amid competitive advantages.

17 авг. 2026 г., 23:11 UTC

Ocular Therapeutix Inc's shares are higher in after-market trading, continuing a strong performance since Monday's close and reaching a notable high.

14 авг. 2026 г., 19:46 UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

13 авг. 2026 г., 23:16 UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

12 авг. 2026 г., 20:01 UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

11 авг. 2026 г., 23:21 UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

10 авг. 2026 г., 20:06 UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

7 авг. 2026 г., 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6 авг. 2026 г., 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

5 авг. 2026 г., 21:03 UTC

Ocular Therapeutix Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains under pressure.

3 авг. 2026 г., 20:06 UTC

Social Media
News

Ocular Therapeutix shares rise after reporting Q2 revenue of $13.5 million, exceeding estimates, and announcing plans for a new drug application for AXPAXLI.

31 июл. 2026 г., 21:01 UTC

Ocular Therapeutix Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid rising inflation concerns.

30 июл. 2026 г., 19:39 UTC

Ocular Therapeutix shares are higher today, continuing an upward trend since Wednesday. The U.S. Dollar Index decline may be influencing broader market dynamics.

28 июл. 2026 г., 19:06 UTC

News

Ocular Therapeutix shares are lower amid broader market volatility and regulatory challenges, reaching a session low earlier today.

27 июл. 2026 г., 21:01 UTC

Ocular Therapeutix Inc. shares are higher in after-market trading, reaching a peak shortly after the session began amid improved European market sentiment.

22 июл. 2026 г., 18:36 UTC

Social Media

Ocular Therapeutix is presenting at the HC Wainwright conference, but shares are declining and remain below their 20-day moving average.

21 июл. 2026 г., 23:41 UTC

Ocular Therapeutix Inc shares rose in after-market trading, reaching their highest cumulative return of the day. The stock remains below its 20-day moving average.

20 июл. 2026 г., 19:46 UTC

Social Media

Ocular Therapeutix shares are lower today, continuing a downward trend. Early gains were followed by a pullback amid uncertain investor sentiment.

Сравнение c конкурентами

Изменение цены

Ocular Therapeutix Inc Прогноз

Целевая цена

By TipRanks

142.29% рост

Прогноз на 12 месяцев

Средняя 25.78 USD  142.29%

Максимум 31 USD

Минимум 18 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Ocular Therapeutix Inc  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

10 ratings

10

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

62 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat